Brought to you by 
Versicor licenses rights to Lilly antifungal
24 Mar 2000
Executive Summary
Versicor (anti-infectives) licensed rights to Lilly's LY303366, a semi-synthetic derivative of the natural product echinocandin B, for the treatment of severe fungal infections.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Versicor licenses rights to Lilly antifungal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice